We may earn a commission. How we review
MEDVi Reviews (2026): 4.3★ Trustpilot, BBB F and an FDA Warning
Is MEDVi worth considering for GLP-1 treatment?
MEDVi is worth comparing if you want a choice between an injectable and an oral compounded GLP-1 program. Its injection was advertised at $179 for the first month and $299 for refills when we checked on September 3, 2026. At those rates, twelve months would cost $3,468. That renewal total is more useful than the introductory price alone, but confirm today's checkout terms before paying. MEDVi also has a substantial customer-review record.
Our practical take: Format choice is the draw, while price clarity and trust are the decision points. The FDA warning letter concerns misleading labeling and marketing of compounded medication, not a finding that the medication was unsafe. Read our MEDVi versus Embody comparison for the side-by-side costs and trade-offs.
About MEDVi
MEDVi offers a weekly compounded GLP-1 injection and a daily compounded tablet. The injection is $179 for month one and $299 for refills. Trustpilot is 4.3 out of 5 across 14,680 reviews, while BBB is F/not accredited. FDA warning letter #721455 concerns misleading labeling and marketing, not an allegation that the medication was unsafe.
Summarize this review with
The price
Price checked 2026-09-03First-month rate on the landing page, where the banner labels it a summer sale, so it can lapse without notice (verified 2026-09-03)
View this planfirst month, then $299/mo
Plans & payment terms
View treatment options at MEDVi. Confirm the latest price and availability there.
What they offer
Why consider it
you specifically need oral and injectable compounded formats under one program and you have read the FDA letter, BBB record and renewal terms.
- One of the few compounded providers offering both oral tablets and injectable semaglutide
- The landing page says the program is HSA and FSA eligible and includes dietician visits and care coaching, with a footnote making that subject to insurance and copay eligibility
- Sleek onboarding experience with clear progress tracking through their patient portal
Worth knowing
you want the strongest regulatory record, a high BBB grade, or a flat monthly price with no first-month step-up.
- FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication
- Its third-party records conflict: 4.3 out of 5 across 14,680 Trustpilot reviews with 12 percent of them at one star, against an F and no accreditation at the BBB
- The $179 semaglutide price covers month one only; the FAQ on MEDVi's own landing page says refills are locked in at $299 a month, making the first year $3,468 rather than $2,148
What customers say
MEDVi's third-party record is sharply split: its Trustpilot profile carries a 4.3 out of 5 TrustScore across 14,680 reviews with 12 percent of them at one star, while its BBB profile is an unaccredited F. Praise centers on fast approval and responsive support; recurring complaints center on billing confusion and slow refunds. Separately, FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing of compounded GLP-1s. The letter concerns misbranding, not an allegation that the medication was unsafe.
Read customer evidence →Coverage & care
- Availability
- Not published. MEDVi's terms say "The Services are currently available to individuals located in certain states" and give the list only by emailing customer service. No state count or state list is shown on the site's contact, about, terms or FAQ pages (rendered check 2026-09-03)
- Insurance
- Not accepted
- Consultation
- included
- Shipping
- free
Cancel by email or patient-portal chat at least 72 hours before the next billing date. Monthly charges are not refunded for the current or prior months; multi-month plans refund only months for which no medication shipped. Medical disqualification is refundable.
Independent research, not medical advice. Read our safety checks and sources.
All plans, payment and cancellation terms
- Consultation
- Included
- Shipping
- Free
- Insurance
- Not accepted
- Availability
- Not published. MEDVi's terms say "The Services are currently available to individuals located in certain states" and give the list only by emailing customer service. No state count or state list is shown on the site's contact, about, terms or FAQ pages (rendered check 2026-09-03)
Cancellation and refunds: Cancel by email or patient-portal chat at least 72 hours before the next billing date. Monthly charges are not refunded for the current or prior months; multi-month plans refund only months for which no medication shipped. Medical disqualification is refundable.
First-year cost & how MEDVi compares
Year 1 uses the compounded semaglutide injection path on MEDVi's landing page: $179 for month 1 plus 11 months at $299 = $3,468. Tablets and the brand-name paths are priced separately, so confirm the exact checkout rate before paying.
| Provider | From | Year 1 total | Score |
|---|---|---|---|
| MEDVi (reviewed) | N/A | $3,468 | N/A |
| Embody | from $69/mo | Not available | 7.3/10 |
| TrimRx | published $149/mo total not verified | Not available | 5.3/10 |
Year 1 totals are shown only where a flat rate, an explicit annual total, or both an introductory and renewal rate are documented. Insurance, FSA/HSA, and promo pricing not included. Compare a deeper price breakdown on the cheapest GLP-1 providers page.
Want the standalone record? MEDVi pricing, every tier with verification dates and detected promotions.
All pricing tiers
Injectable Semaglutide (first month)
$179 View details ↗First-month rate on the landing page, where the banner labels it a summer sale, so it can lapse without notice (verified 2026-09-03)
Injectable Semaglutide (ongoing)
$299 View details ↗Ongoing monthly rate for injectable compounded semaglutide
GLP-1 Tablets (starting)
$249 View details ↗Starting rate on the landing page; the ongoing tablet rate is not published (verified 2026-09-03)
Wegovy or Zepbound membership
$99 View details ↗Monthly membership shown on the brand-name cards. The medication cost is added on top and is not published, and availability is subject to change (verified 2026-09-03)
Why we reached this verdict
MEDVi sells a weekly compounded GLP-1 injection at $179 for the first month and $299 for refills, daily compounded GLP-1 tablets from $249, and brand-name Wegovy and Zepbound on a $99 membership plus a medication cost it does not publish. The injection path is $3,468 over the first year. Tirzepatide, which the February 2026 FDA warning letter shows MEDVi was selling in December 2025, is no longer named anywhere on its site (rendered check 2026-09-03). Its trust record is not a clean yes or no. Trustpilot is 4.3 out of 5 across 14,680 reviews with 12 percent at one star, the BBB grade is F, and FDA warning letter #721455 cites misleading labels and website claims about compounded drugs. The FDA letter concerns misbranding and implied equivalence with approved brands; it does not allege unsafe medication. MEDVi's terms and site footer name three partner pharmacies, Triad Rx in Daphne Alabama, RedRock in St. George Utah and Beaker in McKinney Texas, although we did not independently re-verify their licenses in this pass. The result is useful format flexibility with material regulatory, billing and disclosure caveats, reflected in our 5.7/10 score.
What makes it different: A daily dissolvable GLP-1 tablet and a weekly compounded injection in one program, plus brand-name Wegovy and Zepbound on a $99 membership.
MEDVi Pros and Cons
What We Like
What We Like
- +One of the few compounded providers offering both oral tablets and injectable semaglutide
- +The landing page says the program is HSA and FSA eligible and includes dietician visits and care coaching, with a footnote making that subject to insurance and copay eligibility
- +Sleek onboarding experience with clear progress tracking through their patient portal
- +$179 covers the first month of compounded semaglutide on MEDVi's landing page, including physician review, the personalized plan, medication and free shipping
What Could Be Better
What Could Be Better
- −FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication
- −Its third-party records conflict: 4.3 out of 5 across 14,680 Trustpilot reviews with 12 percent of them at one star, against an F and no accreditation at the BBB
- −The $179 semaglutide price covers month one only; the FAQ on MEDVi's own landing page says refills are locked in at $299 a month, making the first year $3,468 rather than $2,148
- −Brand-name Wegovy and Zepbound paths add a $99 membership plus a medication cost the page does not publish, and the same page's hero says "No membership or hidden fees!" directly above those cards; availability is subject to change
- −No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms
Is MEDVi legit? Pharmacy, prescribers and safety checks
MEDVi is a real, operating telehealth company, but "legit" needs qualification: the FDA issued warning letter #721455 on 2026-02-20. It holds 4.3 out of 5 across 14,680 Trustpilot reviews, while its BBB profile reads F (not accredited). It scores 5.7/10 on our methodology; the six signals below are how we checked.
Six trust signals, the evidence behind them, and what remains unverified.
FDA warning letter #721455
Issued 2026-02-20. Misbranding under FDCA 502(a) and 502(bb): MEDVi-branded product labels implied MEDVi compounded the drugs when it did not, and website claims comparing compounded semaglutide and tirzepatide with FDA-approved brands implied equivalence or FDA evaluation the compounded products do not have.
Received an FDA warning letter on Feb 20, 2026 (ref #721455) for misleading labeling and marketing of compounded GLP-1s. The letter does not allege unsafe medication and does not establish the dispensing pharmacy's current identity, license, or facility type.
Read the official FDA letterSafety & legitimacy
Telehealth GLP-1 platforms vary widely on what they disclose publicly. These six signals are the YMYL bar we check on every review. "Not disclosed" is itself a finding.
MEDVi's terms and site footer name these three partner pharmacies, Triad Rx in Daphne Alabama, RedRock in St. George Utah and Beaker in McKinney Texas, but do not identify which one would compound a particular prescription. We did not independently re-verify their state licenses in this pass (checked 2026-09-03).
How we reviewed MEDVi
Verified September 3, 2026 · Method: public-source verification (no signup)
- ✓FDA warning letter #721455, issued February 20, 2026 to MEDVi, LLC dba MEDVi, verified on fda.gov
- ✓MEDVi's landing page: $179 first month and $299 refills for the compounded weekly injection, $249 starting for daily tablets, and a $99 membership plus an unpublished medication cost for Wegovy and Zepbound
- ✓Medical networks named on the landing page: OpenLoop Health and CareGLP Affiliated P.C.s
- ✓Partner pharmacies named in MEDVi's terms and site footer: Triad Rx (Daphne, AL), RedRock Pharmacy (St. George, UT) and Beaker Pharmacy & Compounding (McKinney, TX)
- ✓Cancellation requires 72 hours' notice before billing; current-month monthly charges are non-refundable
- ✓Trustpilot 4.3 out of 5 across 14,680 reviews, with 12 percent at one star, and BBB F/not accredited
- ✓MEDVi's terms limit service to individuals located in certain states and give the state list only on request to customer service
- ⚠Whether FDA considers the February 2026 violations corrected; no close-out letter appeared on the official record as of this check
- ⚠Independent state-license verification for the two pharmacies named in MEDVi's terms
- ⚠The all-in monthly cost of the brand-name Wegovy and Zepbound paths, since the site publishes only the $99 membership
- ⚠Which states MEDVi actually serves, and the BBB complaint volume behind its F grade
- ⚠Individual prescriber names and credentials assigned before checkout
We did not sign up for MEDVi as part of this review. Findings are based on the provider's public site, product pages, official FAQ, and third-party regulatory or review-aggregator data where available. See our editorial policy for the full methodology.
Clinical evidence: 14.9% average body-weight reduction at 68 weeks in STEP-1 (NEJM, 2021). Individual results vary; compounded GLP-1s are not FDA-approved.
What the doctors say about GLP-1 medications
Independent, sourced clinical context on the medication class, not a comment on this provider.
“Our research highlights the safety and the potential for GLP-1 receptor agonists to reduce the risk of acute pancreatitis recurrence in individuals with obesity and type 2 diabetes, challenging previous concerns and offering new hope for effective disease management.”
“More options for people with these challenging diseases will be very helpful, particularly if the new oral tablet medicines are priced reasonably.”
Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.
MEDVi reviews: what customers say
Recorded third-party ratings and source links for MEDVi. “Not verified” means this review has no confirmed figure; it does not establish that no profile exists.
MEDVi's third-party record is sharply split: its Trustpilot profile carries a 4.3 out of 5 TrustScore across 14,680 reviews with 12 percent of them at one star, while its BBB profile is an unaccredited F. Praise centers on fast approval and responsive support; recurring complaints center on billing confusion and slow refunds. Separately, FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing of compounded GLP-1s. The letter concerns misbranding, not an allegation that the medication was unsafe.
How MEDVi works
Health Assessment + Preference Selection
Complete your health profile and indicate your preference for oral tablets or injectable semaglutide. MEDVi's intake specifically addresses needle concerns and GI sensitivity.
Provider Consultation
An OpenLoop Health clinician meets with you after checkout to decide whether a prescription is appropriate. Oral or injectable is your choice. No micro-dosing or below-standard starting dose is offered on the site's landing, home, about, terms or FAQ pages (rendered check 2026-09-03).
Treatment + Progress Tracking
Medication ships free. Track your weight, side effects, and milestones through MEDVi's patient portal. Transition from oral to injectable anytime.